System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Pascal Chanez is an expert in Pulmonology at Hôpitaux universitaires de Marseille (France). As of October 2026, ScienceLeadR ranks Pascal Chanez in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Pascal Chanez has authored 701 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 7 of them ongoing. SLR score: 2,401 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Pascal Chanez Hôpitaux universitaires de Marseille France
2 401 ScienceLeadR Reputation 2401

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Immunology - Critical Care - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 701

Citations

Citations: 52 023 1st author: 58 Last author: 128 Unique author: 6

Main journals

Rev Mal Respir 79
Eur Respir J 62
J Allergy Clin Immunol 50
Allergy 38
Am J Respir Crit Care Med 38

Best Journals

N Engl J Med 13
Lancet Respir Med 6
Lancet 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of Pollen Exposure on Health and Exercise Performance: A Scoping Review.
PMID 42532126 — exercise, sports medicine, sports		Int J Sports Med20260
Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.
PMID 42423296 — blood, hypersensitivity, eosinophils, biomarkers, sputum, asthma		Allergy20260
Clinical Features of Cellular Senescence Pathways in Severe Asthma.
PMID 42315480 — genes, hypersensitivity, cellular senescence, polyps, biopsy, genes, p53, asthma, nasal polyps		Allergy20261
An Ex Vivo Model of Post Infectious Bronchiolitis Obliterans in Children Using Reconstituted Human Bronchial Epithelium.
PMID 42194084 — cells, mucins, epithelial cells, alarmins, biopsy, bronchiolitis obliterans, epithelium, bronchiolitis, antiviral agents, child		Biomolecules20260
Clinical response progression to benralizumab using computed tomography: Prognostic BenraliScan study.
PMID 42106061 — lung, blood, tomography, eosinophils, biomarkers, asthma, biological therapy, prognosis		Chest20260

Clinical Studies 43

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 20
N/A 11
Phase 2 7
Phase 4 5

By status:

Completed 27
Recruiting 7
Unknown 4
Terminated 3
Active not recruiting 2

By type:

Interventional 39
Observational 4

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 2
multicentric5to9 4
multicentricup10 28

Main Topics

Cohort/Consortium Investigators 18

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
2023-507407-59-00 — multiple chronic conditions, pulmonary disease, chronic obstructive, fumarates, metered dose inhalers, formoterol fumarate, therapeutics, lung diseases, lung diseases, obstructive, budesonide		Phase 3Recruiting2024
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged 40 to 85 years with chronic obstructive pulmonary disease
2025-521268-37-00 — lung, respiratory tract diseases, aged, pulmonary disease, chronic obstructive, lung diseases, lung diseases, obstructive		Phase 4Recruiting2025
An open label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00 — maintenance, therapeutics, asthma		Phase 3Active not recruiting2024
A Study to evaluate the long term safety and tolerability of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations
2025-523690-41-00 — safety, pulmonary disease, chronic obstructive, lung diseases, history, lung diseases, obstructive		Phase 3Recruiting2026
EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY
NCT06334705 — epidemiology, blood, healthy volunteers, food, calcium, prevalence, sleep apnea syndromes, asthma, hematologic tests, consent forms		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS